NVCT — Nuvectis Pharma Balance Sheet
0.000.00%
- $194.42m
- $167.62m
Annual balance sheet for Nuvectis Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0 | 5.74 | 20 | 19.1 | 18.5 |
| Total Other Current Assets | |||||
| Total Current Assets | 0 | 5.83 | 20.4 | 19.2 | 18.6 |
| Other Long Term Assets | |||||
| Total Assets | 0 | 6.66 | 20.4 | 19.2 | 18.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.01 | 2.42 | 6.19 | 6.98 | 8.89 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.01 | 2.42 | 6.19 | 6.98 | 8.89 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -0.01 | 4.24 | 14.2 | 12.2 | 9.71 |
| Total Liabilities & Shareholders' Equity | 0 | 6.66 | 20.4 | 19.2 | 18.6 |
| Total Common Shares Outstanding |